OncoSwab develops a non-invasive diagnostic tool utilizing nasal swabs for the early detection of lung cancer. This method analyzes cellular markers via machine learning algorithms to assess nodule malignancy risk with high diagnostic yield. The technology aims to improve patient comfort by reducing the need for invasive procedures like biopsies and accelerating clinical decision-making.
Funding
$40K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for lung cancer screening often involve invasive procedures and costly imaging, leading to discomfort, risk, and delays in diagnosis, particularly for individuals with pulmonary nodules. These methods can also yield inconclusive results, necessitating further invasive follow-ups.
Solution
OncoSwab has developed a non-invasive lung cancer screening test that analyzes nasal fluids to detect cancer cells, offering a more accessible and precise way to assess nodule malignancy risk. The test is designed for self-testing and point-of-care use, eliminating the need for specialized medical personnel and reducing the discomfort and risks associated with invasive procedures. By providing earlier and more accurate assessments of lung nodules, OncoSwab helps clinicians make informed decisions sooner, potentially reducing the need for unnecessary invasive follow-ups and leading to significant cost savings. The technology targets higher-risk individuals, especially those with incidental pulmonary nodules.
Target Audience
The primary target audience includes individuals at higher risk for lung cancer, particularly those with incidental pulmonary nodules, as well as clinicians seeking earlier and more accurate methods for assessing nodule malignancy risk.
Features
- Non-invasive nasal swab test eliminates discomfort and risk associated with invasive procedures.
- Compatible with self-testing and point-of-care sites, removing the need for specialized medical personnel.
- Provides faster and more accessible testing for higher-risk individuals with incidental pulmonary nodules.
- Offers earlier, more accurate assessments of lung nodules compared to traditional methods.
- Patent-pending technology provides a precise way to assess nodule malignancy risk.